Business Context and Reporting Period
This Form 8-K filing by Obalon Therapeutics, Inc. (trading symbol: OBLN) reports executive leadership changes effective October 19, 2019. The report was filed on October 24, 2019. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive appointments and compensation adjustments.
Material Changes
- Executive Appointments: William Plovanic was appointed Chief Executive Officer (CEO) and retains the title of President. Nooshin Hussainy was appointed Chief Financial Officer (CFO).
- Compensation Adjustments:
- Mr. Plovanic's annual base salary increased from $400,000 to $510,000.
- Mr. Plovanic received a one-time cash bonus of $200,000.
- Ms. Hussainy's annual base salary increased from $250,000 to $300,000.
- Equity Grants:
- Mr. Plovanic received an option to purchase 10,000 shares.
- Ms. Hussainy received options to purchase 11,682 shares and 9,000 shares.
- Exercise prices are based on the closing price on October 25, 2019.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, risk factors, or management commentary regarding business operations or financial outlook. The vesting schedules for the new stock options are tied to the executives' continued service over a four-year period.
Investor Verification Checklist
- Verify the closing stock price on October 25, 2019, to determine the exercise price of the granted options.
- Review the Definitive Proxy Statement (Schedule 14A) filed on June 13, 2019, for detailed background on the new executives.
- Confirm the impact of the $200,000 one-time bonus and salary increases on the company's immediate cash burn rate.
- Monitor future filings for the company's financial performance, as this 8-K contains no operational data.